Analystreport

Intellia Therapeutics Inc (NASDAQ: NTLA) is now covered by analysts at Truist. They set a "buy" rating and a $40.00 price target on the stock.

Intellia Therapeutics, Inc.  (NTLA) 
Last intellia therapeutics, inc. earnings: 2/27 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: ir.intelliatx.com/investor-overview